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a b s t r a c t
The activation and subsequent platelet aggregation play a key role in the formation of arterial
thrombosis and therefore is the key therapeutic target in the treatment of acute coronary
syndromes. Dual antiplatelet therapy containing aspirin and P2Y12 ADP receptor antagonist
forms currently the basis in acute ST – elevation myocardial infarction (STEMI) pharmacologi-
cal treatment. Nevertheless, there is a wide variability in pharmacodynamic response to
administration of clopidogrel, the most frequently used P2Y12 ADP receptor antagonist. High
platelet reactivity after clopidogrel administration is associated with increased risk of stent
thrombosis and points to the suitability of laboratory monitoring of antiplatelet therapy
efﬁcacy in clinical practice. Laboratory monitoring of antiplatelet therapy by ex vivo platelet
function tests may help to identify individuals with poor antiplatlet response. Recently, there
is a growing number of data reporting a failure in antiplatelet response following clopidogrel
administration, which is speciﬁcally associated with insulin resistance and diabetes mellitus.
Prasugrel, a new, potent P2Y12 ADP receptor antagonist, provides faster and more consistent
inhibition of platelet function compared with clopidogrel. Prasugrel therapy was repeatedly
described as an effective method to overcome clopidogrel resistance and prasugrel resistance
has not yet been reliably described. We report two cases of patients with diabetes mellitus type
2 at the stage of organ complications, in whom a prasugrel loading dose of 60 mg did not reach
adequate antiplatelet response in 60 min after prasugrel administration. The antiplatelet
response was measured by light transmission aggregometry and by VASP protein phosphor-
ylation assessment.
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The activation and subsequent platelet aggregation play a key
role in the formation of arterial thrombosis and therefore is the
key therapeutic target in the treatment of acute coronary
syndromes (ACS). Dual antiplatelet therapy containing aspirin
and P2Y12 ADP receptor antagonist forms currently the basis
in acute ST – elevation myocardial infarction (STEMI)
pharmacological treatment. The current intervention of
several complementary ways of platelet activation and
aggregation is necessary to ensure effective treatment and
prevention of coronary thrombosis. The introduction of P2Y12
ADP receptor antagonists has made a major advance in the
ACS treatment. Thienopyridine clopidogrel given in the CURE
study (Clopidogrel in Unstable Angina to Prevent Recurrent
Events) in patients with ACS signiﬁcantly reduced the
incidence of cardiac death and nonfatal myocardial infarction
or stroke compared with patients treated with aspirin alone
[1]. A 600 mg clopidogrel loading dose leads to a faster onset of
action and has a greater platelet inhibitory effect than a
loading dose of 300 mg [2,3]. Nevertheless, there is a wide
variability in pharmacodynamic response to administration of
clopidogrel, which is linked to several factors, including
genotype polymorphisms [4]. High platelet reactivity after
clopidogrel administration is associated with increased risk of
stent thrombosis and other ischemic events [5,6]. High
variability in antiplatelet response to clopidogrel administra-
tion, points to the suitability of laboratory monitoring of
antiplatelet therapy efﬁcacy in patients with acute coronary
syndrome. Laboratory monitoring of antiplatelet therapy by ex
vivo platelet function tests may help to identify individuals
with poor antiplatelet response [7]. High platelet reactivity
after clopidogrel administration is also major reason for the
introduction of new P2Y12 ADP receptor antagonists with
more favorable pharmacodynamic proﬁle to clinical practice
[8].
Diabetes mellitus is a strong, independent risk factor of
acute STEMI. Diabetes mellitus (DM) aggravates the course of
ACS and increases the risk of its complications including
cardiogenic shock and death [9]. Diffuse coronary involvement
[10,11], diabetic cardiomyopathy, an imbalance of the auto-
nomic nervous system, decreased ability to develop collateral
circulation [12] and metabolic disorders causing ineffective
and increased oxygen consumption by myocardial tissue
during ischemia and during increased load [13] are the main
factors responsible for worsen prognosis in diabetic patients
with ACS. However, abnormal platelet function and coagula-
tion disorders described in diabetic patients may also
contribute in future risk of thrombotic events in diabetic
ACS patients. Although several large clinical trials have
demonstrated the efﬁcacy of clopidogrel in the treatment of
ACS, there is growing amount of data about failure in
antiplatelet response after clopidogrel administration, which
is speciﬁcally associated with insulin resistance and DM
[14,15]. This incomplete antiplatelet response may contribute
to a worse prognosis of acute myocardial infarction in patients
with diabetes mellitus. Above mentioned reports are based on
ex vivo testing of platelet reactivity in clopidogrel therapy, as
well as on the sub-analysis of clinical trials among subjectswith DM, which consistently showed worse clinical outcome
and an increased incidence of stent thrombosis in patients
with DM [16–20]. Platelet reactivity in clopidogrel treatment
>50% is associated with higher risk of ischemic events after
percutaneous coronary intervention (PCI) [17].
Prasugrel is a new, potent, P2Y12 ADP receptor antagonist.
Prasugrel provides more consistent inhibition of P2Y12 ADP
receptor and has lower intraindividual variability in efﬁcacy
compared with clopidogrel. Beneﬁt of prasugrel therapy seems
to be the highest in patients with diabetes mellitus [21].
According to the prasugrel SPC (summary of product char-
acteristics), a loading dose of 60 mg reaches full antiplatelet
effect after 15 min when stimulation with 5 mmol/l adenosine
diphosphate (ADP) is used and after 30 min when stimulation
with 20 mmol/l ADP is used. Prasugrel therapy was repeatedly
described as an effective method to overcome clopidogrel
resistance [22,23] and up to very rare case reports of
incomplete antiplatelet response after prasugrel administra-
tion [24]; prasugrel resistance has not been reliably described.
We report two cases of patients with diabetes mellitus type
2 at the stage of organ complications, in whom a prasugrel
loading dose of 60 mg did not reach adequate antiplatelet
response not even in 60 min after administration of prasugrel.
The antiplatelet response was measured by light transmission
aggregometry (10 mmol/l ADP) and by VASP protein phosphor-
ylation assessed using ﬂow cytometry.
2. Case reports
2.1. Case no. 1
63-year-old obese (height 184 cm, weight 105 kg, BMI 31)
patient with diabetes mellitus type 2 (A1C 5.6%) on conven-
tional insulin therapy regimen using insulin analogs, with
permanent atrial ﬁbrillation, was admitted to internal depart-
ment for urgent coronary angiography realization for acute
anterior STEMI, with 2 h ischemia time. Urgent coronary
angiography revealed critical stenosis of the middle part of the
Left anterior descending coronary artery (LAD). Primary
percutaneous coronary intervention (pPCI) on LAD was
performed with an implantation of bare metal coronary stent
(BMS) with a good angiographic effect (Fig. 1).
After diagnostic ECG taking in prehospital phase (11:35),
the patient immediately received a 60 mg prasugrel loading
dose together with aspirin loading dose (400 mg) and 10,000 IU
of unfractionated heparin intravenously. After arrival to the
catheterization laboratory, 1 hour after ADP antagonist
loading dose administration (12:36), ﬁrst blood sample was
taken in order to assess the efﬁcacy of antiplatelet therapy.
This sample was processed under standard preanalytic
conditions immediately and examined by light transmission
aggregometry (LTA) using ADP inducer in concentration of
10 mmol/l and by VASP protein phosphorylation measuring
using ﬂow cytometry within 1 h from sample taking. First
examination by LTA as well as by VASP protein phosphor-
ylation assessment showed a lack of prasugrel loading dose
efﬁcacy-platelet aggregation rate after ADP induction of 57%
(reference value <50%), VASP phosphorylation rate 72%
(reference value <50%) (Fig. 2).
Fig. 1 – urgent coronary angiography of left coronary artery with critical stenosis of the middle part of the LAD and
angiography after pPCI on LAD with BMS implantation.
Fig. 2 – VASP protein phosphorylation assessment protocol in diabetic patient with insufficient antiplatelet response after
prasugrel loading dose.
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procedure, second blood sampling was done. Second blood
sample was taken one hour after administration of the ﬁrst
prasugrel maintenance dose (10 mg), 19.5 h after prasugrel
loading dose administration. Sample was examined by above
mentioned preanalytic and analytic conditions using LTA
and VASP protein phosphorylation assessment. Efﬁcacy ofantiplatelet therapy measured at the second testing was
adequate enough: platelet aggregation after ADP induction
17%, VASP phosphorylation rate 17%.
In the course of further patient hospitalization no other
severe complications, except of mild signs of left heart failure
(cracles to 1/3 lung ﬁelds and intolerance of horizontal
position) managed by administration of parenteral diuretic
Fig. 3 – urgent coronary angiography of right coronary artery with its acute closure and angiography after pPCI on RCA with
implantation of 2 BMS.
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in good general condition after the initiation of rehabilitation.
In this case stent thrombosis did not occur.
2.2. Case no. 2
68-year-old obese (height 168 cm, weight 98 kg, BMI 35) patient
with type 2 diabetes in the stage of organ complications (A1C
7.0%) with 30 years disease duration, on metformin and
intensiﬁed insulin regimen treatment, was admitted to internal
department for urgent coronary angiography realization for
acute inferior STEMI with III. degree AV block and 3.5 h ischemia
time. Urgent coronary angiography revealed multivessel dis-
ease with an acute closure of right coronary artery (RCA). Right
after the insertion of acute pacemaker electrode, pPCI on RCA
was performed with an implantation of 2 BMS. A good
angiographic effect was seen after coronary intervention. (Fig. 3)
After diagnostic ECG taking in prehospital phase (10:12), the
patient immediately received a 60 mg prasugrel loading dose
together with aspirin loading dose (400 mg) and 10,000 IU of
unfractionated heparin intravenously. After arrival to the
catheterization laboratory, 1 hour after ADP antagonist loading
dose administration (11:16), ﬁrst blood sample was taken in
order to measure the efﬁcacy of antiplatelet therapy. Exami-
nation of the ﬁrst sample by LTA and VASP protein
phosphorylation assessment showed an incomplete prasugrel
loading dose efﬁcacy-platelet aggregation after ADP induction
54% (reference value <50%), VASP phosphorylation rate 84%
(reference value <50%).
The efﬁcacy of antiplatelet therapy measurement at the
second testing, 1 h after administration of the ﬁrst prasugrel
maintenance dose (10 mg) and 20 h after administration of
prasugrel loading dose in this patient showed an already
sufﬁcient antiplatelet response on prasugrel treatment: platelet
aggregation after ADP induction 19%, VASP phosphorylation
rate 22%.
During the patient's further stay at the hospital, a
progressive recovery of AV conduction with the ability to stopthe urgent pacemaking was reached and the patient was all
the time hemodynamically stable, without any signs of heart
failure. Patient was in good general condition released to
outpatient care right after beginning of rehabilitation. In this
case stent thrombosis after pPCI of culprit lesion did not occur
either.
3. Discussion and review of literature
3.1. Dual antiplatelet therapy, antiplatelet drug resistance
and its importance in clinical practice
Dual antiplatelet therapy signiﬁcantly improves the outcome
of acute STEMI treatment and reduces both short-term as well
as long-term mortality in patients with acute STEMI [25].
Clopidogrel administered in the CURE study in patients with
ACS signiﬁcantly reduced the incidence of cardiac death and
nonfatal myocardial infarction or stroke compared with
patients treated with aspirin alone [1]. Variability in pharma-
codynamic response/resistance to clopidogrel is currently
widely discussed problem in clinical practice. High platelet
reactivity after clopidogrel administration is associated with
increased risk of stent thrombosis and other ischemic events
[5,6]. Variability of antiplatelet response to clopidogrel is
associated with several factors, such as variability of clopido-
grel absorption, variability of the active metabolite creation, or
a variability in P2Y12 receptor antagonist activity [4]. These
factors may be inﬂuenced by both genetic polymorphisms,
together with several environmental factors, such as different
drug interactions at the level of CYP P 450 2C19 and 3A4, or at
the level of P-glycoprotein [4,26,27]. However, variability in
antiplatelet response to clopidogrel may be also associated
with other, currently not well understood factors. Recently,
there is growing number of data reporting a failure in
antiplatelet response following clopidogrel administration,
which is speciﬁcally associated with insulin resistance and
diabetes mellitus [14,15].
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resistance in diabetic patients
Diabetes mellitus is a strong, independent risk factor for acute
STEMI [9]. One of the possible explanations for poorer
prognosis of diabetic patients with ACS may be also an
insufﬁcient efﬁcacy of treatment in the presence of this
metabolic disorder. Several recently published studies showed
worse clinical outcome and an increased incidence of stent
thrombosis in patients with diabetes mellitus [16–20]. Diabetic
patients treated with clopidogrel have signiﬁcantly higher
platelet aggregation after ADP stimulation compared with
nondiabetic subjects and signiﬁcantly higher number of non -
responders to clopidogrel administration can be also seen in
the group of diabetic patients [19]. Platelet reactivity in
clopidogrel treatment >50% is consequently associated with
higher risk of ischemic events after PCI [17]. Patients with
diabetes have lower clinical effect from clopidogrel treatment,
what was consistently referred in results of several published
randomized trials with clopidogrel [1,28–30]. However, the
mechanism of clopidogrel resistance in patients with diabetes
remains unclear. Erlinge et al. [15] showed a signiﬁcantly
higher incidence of insufﬁcient antiplatelet response in group
of patients treated with clopidogrel compared with those with
prasugrel therapy. Diabetic patients were more frequently
represented in the group with inadequate platelet response to
clopidogrel. It is interesting, that in this trial, platelets of
diabetic patients with inadequate antiplatelet response after
clopidogrel administration responded well to ex vivo admin-
istration of clopidogrel active metabolite. This ﬁnding indi-
cates a low level of resistance on P2Y12 ADP platelet receptor
and supports potential interaction between DM and pharma-
cokinetic processes of clopidogrel metabolism. High variability
of antiplatelet response to clopidogrel administration sup-
ports the effort to identify individuals with poor response by
laboratory methods [7] and is one of the reasons for the
introduction of new ADP P2Y12 receptor antagonists with
more favorable pharmacodynamic proﬁle to clinical practice
[8].
3.3. Prasugrel and prasugrel resistance in acute coronary
syndrome patients
Prasugrel, a new, potent, irreversible tienopyridine P2Y12 ADP
receptor antagonist, provides faster and more consistent
inhibition of platelet function compared with clopidogrel
[21]. The response to prasugrel is not affected by CYP2C19
inhibitors, loss of CYP2C19 gene function, or decreased
function of P-glycoprotein [31]. The TRITON-TIMI 38 study
[21], which compared prasugrel and clopidogrel in patients
with ACS without prior ADP receptor antagonist therapy
showed, that prasugrel signiﬁcantly reduced the incidence of
the combined primary endpoint (cardiac death, nonfatal MI,
stroke), the risk of myocardial infarction and the risk of stent
thrombosis. Beneﬁt of prasugrel treatment was the most
signiﬁcant in the group of diabetic patients, in whom prasugrel
therapy signiﬁcantly reduced the risk of ischemic events,
including the risk of recurrent MI and the risk of stent
thrombosis, without increasing the risk of serious bleeding
complications. Prasugrel therapy was repeatedly described asan effective method to overcome clopidogrel resistance [22,23].
Silvano et al. described a rare case of resistance to both
clopidogrel and prasugrel in non-diabetic patient with acute
STEMI due stent thrombosis [24]. However, this patient did not
receive prasugrel loading dose and was treated only with
prasugrel maintenance dose. Abnormal metabolism of anti-
platelet drugs due to reduced activity of CYP P 450, the main
enzyme complex responsible for the active tienopyridine
antagonists metabolite formation [32–34], was considered to
be the most probable mechanism of drug resistance in this
case. Reduced activity due to genetic variability of CYP P450
2C19 and 3A4 was subsequently veriﬁed by genetic testing [24].
Except of this rare case of insufﬁcient antiplatelet response to
prasugrel, prasugrel resistance has not been reliably described.
We describe an insufﬁcient efﬁcacy of prasugrel loading dose
in two patients with type 2 diabetes admitted for acute STEMI,
which was veriﬁed by two independent laboratory methods.
The cause of this insufﬁcient efﬁcacy is currently not clear;
however, most likely it was not caused by a short time interval
from drug administration till blood sample examination.
Prasugrel reaches full antiplatelet response after 30 min of
its submission and examination of prasugrel efﬁciency was
performed in both cases more than an hour after a prasugrel
loading dose administration. Variability in CYP P450 3A4
activity may also affect the rapidity of tienopyridine antago-
nist antiplatelet activity onset [33,34]; however pharmacoki-
netic interactions at this level are not probable in our patients.
None of the presented patients were treated simultaneously
by strong inducers or strong inhibitors of CYP P450 3A4
enzyme. Although the CYP P 450 polymorphisms testing were
not performed in our patients and therefore the impact of low
inherited activity of CYP P450 on insufﬁcient antiplatelet
response cannot be completely excluded, we do not consider
the current occurrence of low metabolic activity CYP P450
polymorphisms in both patients as probable. Diabetes mellitus
itself seems most likely to be the cause of incomplete
antiplatelet response after prasugrel administration in our
patients. The exact mechanism how diabetes affects the
tienopyridine antagonist activity is currently not known.
Erlinge et al. [15] pointed on the fact that platelets of diabetic
patients with poor antiplatelet response to clopidogrel
responded well to ex vivo administration of the active
clopidogrel metabolite. This ﬁnding suggests a low level of
resistance on platelet P2Y12 ADP receptor in diabetes and
supports a potential interaction of diabetes with pharmacoki-
netic processes of clopidogrel metabolism. Whether diabetes
affects pharmacokinetic processes of prasugrel metabolism as
well, or an insufﬁcient efﬁcacy of prasugrel in diabetic patients
is caused by another mechanism remains recently unclear and
further studies will be needed for the ﬁnal clariﬁcation of this
issue. Despite no stent thrombosis appeared in our patients,
high on – treatment platelet reactivity after prasugrel
administration may be clinically important and may contrib-
ute to worse prognosis in diabetic patients with ACS. Obesity is
also connected with ineffective antiplatelet response, what
was previously reported in several studies [35,36]. Both
presented patients were obese and therefore the impact of
obesity on insufﬁcient antiplatelet response cannot be
completely excluded. However, insufﬁcient antiplatelet re-
sponse may be seen also in diabetic individuals with normal
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response in diabetic patients a study comparing antiplatelet
response in obese diabetic and nondiabetic subjects will have
to be performed.
Presented cases of diabetic patients, together with results
of recently published studies [35,38] suggest, that real
prevalence of insufﬁcient antiplatelet response after prasugrel
administration may by higher, than is traditionally consid-
ered. Ideal timing of antiplatelet efﬁcacy examination in
patients with ACS is still being controversial. Prasugrel reaches
full antiplatelet activity in 30–45 min from loading dose
administration (data according to SPC of prasugrel). However,
in fact the data contained in the SPC of this drug were not
obtained in the group of patients with ACS. It is therefore
possible that in this speciﬁc group of patients the data entailed
in the SPC of prasugrel do not fully apply. Benello et al. [38]
pointed on the fact that up to 25% of patients with ACS did not
reach effective antiplatelet response even after 6–12 h from
prasugrel loading dose administration. Despite this fact,
patients with ACS have a high risk of stent thrombosis
immediately after stent implantation. Sufﬁcient antiplatelet
treatment effectively decreases the risk of stent thrombosis.
On the other hand, high on – treatment platelet reactivity had
been repeatedly associated with the risk of thrombotic events
after PCI. Time to peak platelet inhibition after ADP receptor
antagonist administration varies in patients with DM in
contrary to nondiabetic patients [15]. Effective antiplatelet
treatment should be initiated in ACS patients as soon as
possible to prevent future thrombotic events. Optimization of
antiplatelet treatment efﬁcacy remains therefore the impor-
tant objective in the management of patients with acute
STEMI.
Nowadays, there is only limited knowledge about anti-
platelet treatment efﬁcacy in patients with higher stages of
chronic kidney disease. Dember et al. [39] reported that
clopidogrel treatment (loading dose of 300 mg followed by
75 mg daily) administrated in patients with end stage kidney
disease signiﬁcantly reduced the frequency of early thrombo-
sis of new arteriovenous ﬁstulas. Antiplatelet treatment
efﬁcacy was not assessed in this study. Whether kidney
disease impacts the antiplatelet response remains unclear.
Prevalence of chronic kidney disease in patients with DM is
high. It is also known, that kidney diseases may affect the drug
response (interference with pharmacokinetic or pharmacody-
namic processes). However, presented patients did not suffer
from signiﬁcant kidney disease (i.e. stage 3 or higher;
signiﬁcant kidney disease was excluded using creatinine
clearance examination) and therefore the impact of concomi-
tant kidney disease on prasugel insufﬁcient antiplatelet
response is not probable in our patients.
4. Conclusion
Our cases suggest, that insufﬁcient efﬁcacy of antiplatelet
therapy may be one of the factors participating in the worse
prognosis of acute STEMI in diabetic patients. Insufﬁcient
efﬁcacy of antiplatelet therapy in diabetic patients may appear
also when new antiplatelet drugs (such as prasugrel) are used.
Insufﬁcient efﬁcacy of prasugrel appears to be mostly markedin ﬁrst hours after loading dose administration. It is question-
able whether better results of studies with glycoprotein (GP)
IIb/IIIa receptors antagonists in patients with diabetes [40]
were at least partially achieved due to the overlap of
insufﬁcient antiplatelet response of dual antiplatelet therapy
in the ﬁrst hours after its administration. Our results show,
that longer prasugrel administration provides adequate
antiplatelet response even in patients with diabetes and
therefore diabetic patients are at the risk of stent thrombosis
due to the lack of effective antiplatelet therapy especially in
ﬁrst hours after stent implantation. This risk may be reduced
by GP IIb/IIIa receptors antagonist, which will provide
adequate antiplatelet activity to full onset of ADP receptor
antagonist antiplatelet efﬁcacy and thus improve the overall
outcome of treatment in diabetic patients with acute STEMI.
To verify this hypothesis a randomized study examining the
beneﬁt of GP IIb/IIIa receptors antagonist addition to dual
antiplatelet therapy in early in - hospital phase of care in
patients with diabetes admitted for acute STEMI will have to be
performed.
Our cases points on the clinical beneﬁt of antiplatelet
therapy efﬁcacy monitoring, which may be useful not only in
patients with diabetes mellitus. According to our experience,
VASP protein phosphorylation assessment is more sensitive
for screening of antiplatelet efﬁcacy of ADP receptor antago-
nists than LTA. However, light transmission aggregometry is
more available in clinical practice and our cases show, that it is
probably sensitive enough to monitor the efﬁcacy of ADP
receptor antagonist antiplatelet therapy. LTA seems to be a
laboratory method well applicable in a routine clinical
practice. Monitoring of antiplatelet therapy efﬁcacy using ex
vivo platelet function tests may signiﬁcantly help to identify
patients with its insufﬁcient efﬁcacy and allow an early
initiation of effective approach in individualization of anti-
platelet therapy in patients with insufﬁcient response. Routine
introduction of antiplatelet therapy efﬁcacy laboratory moni-
toring in patients with acute coronary syndrome should
become at least an object of consideration in the near future.
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